Drug Target Insights最新文献_第7页

Valacyclovir Neurotoxicity and Nephrotoxicity in an Elderly Patient Complicated by Hyponatremia. 缬昔洛韦对老年低钠血症患者的神经毒性和肾毒性。

IF 2.7

Drug Target Insights Pub Date : 2018-06-25 eCollection Date: 2018-01-01 DOI: 10.1177/1177392818782899

Takuya Murakami, Tetsu Akimoto, Mari Okada, Erika Hishida, Taro Sugase, Atsushi Miki, Marina Kohara, Hiromichi Yoshizawa, Takahiro Masuda, Takahisa Kobayashi, Osamu Saito, Shigeaki Muto, Daisuke Nagata

{"title":"Valacyclovir Neurotoxicity and Nephrotoxicity in an Elderly Patient Complicated by Hyponatremia.","authors":"Takuya Murakami, Tetsu Akimoto, Mari Okada, Erika Hishida, Taro Sugase, Atsushi Miki, Marina Kohara, Hiromichi Yoshizawa, Takahiro Masuda, Takahisa Kobayashi, Osamu Saito, Shigeaki Muto, Daisuke Nagata","doi":"10.1177/1177392818782899","DOIUrl":"https://doi.org/10.1177/1177392818782899","url":null,"abstract":"A 66-year-old women with no history of renal disease was admitted due to a coma and acute kidney injury with a serum creatinine level of 7.44 mg/dL which were ascribed to valacyclovir neurotoxicity and nephrotoxicity, respectively. She had received valacyclovir at a standard dosage for the treatment of herpes zoster and was finally discharged, having fully returned to her normal baseline mental status with a recovered serum creatinine level of 0.68 mg/dL. We feel that awareness of this pathology remains a challenge for physicians and therefore strongly recommend the further accumulation of experiences similar to our own. Our experience underscores the pitfalls of administering valacyclovir to elderly patients who barely appear to have a favorable renal function. Several concerns regarding the therapeutic management, including blood purification strategies, that emerged in this case are also discussed.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"12 ","pages":"1177392818782899"},"PeriodicalIF":2.7,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1177392818782899","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36318018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Anti-CD20 Cell Therapies in Multiple Sclerosis-A Fixed Dosing Schedule for Ocrelizumab is Overkill. 抗cd20细胞治疗多发性硬化症- Ocrelizumab的固定剂量计划是过度杀伤。

IF 2.7

Drug Target Insights Pub Date : 2017-10-25 eCollection Date: 2017-01-01 DOI: 10.1177/1177392817737515

Jagannadha Avasarala

{"title":"Anti-CD20 Cell Therapies in Multiple Sclerosis-A Fixed Dosing Schedule for Ocrelizumab is Overkill.","authors":"Jagannadha Avasarala","doi":"10.1177/1177392817737515","DOIUrl":"https://doi.org/10.1177/1177392817737515","url":null,"abstract":"Anti-CD 20 therapies have found significant uses in multiple sclerosis (MS). Based singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech, and Biogen) in neuroimmunological diseases, ocrelizumab (OCR; Ocrevus, Genentech) was developed as a treatment option for MS and selectively targets CD20 B cells, a cell surface antigen found on pre-B cells, mature, and memory B cells, but not on lymphoid stem cells and plasma cells. On the basis of indirect evidence, elimination of the antigen-presenting capabilities and antigen nonspecific immune functions of B cells appear to be central to the therapeutic efficacy of anti-CD20 B-cell therapies. An important question is this-Why does the drug need to be dosed at fixed intervals and not based on a measurable endpoint, such as tracking peripheral CD20 cell counts? There is minimal scientific validity in infusing the drug every 6 months particularly if CD20 cell counts are negligible in the peripheral blood. In this analysis, a case is made for following CD19 cell populations as a surrogate for CD20 cells on a monthly basis to guide OCR redosing parameters and does not follow a scheduled dosing parameter.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"11 ","pages":"1177392817737515"},"PeriodicalIF":2.7,"publicationDate":"2017-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1177392817737515","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35594183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Ethanol Extract of Stem Bark Show Remarkable Prophylactic Activity in Experimental –Infected Mice 茎皮乙醇提取物对实验性感染小鼠有显著的预防作用

IF 2.7

Drug Target Insights Pub Date : 2017-08-28 DOI: 10.4137/DTI.S42761

Olayinka O Otegbade, J. Ojo, D. Adefokun, O. Abiodun, B. Thomas, O. Ojurongbe

引用次数: 0

Ethanol Extract of Blighia sapida Stem Bark Show Remarkable Prophylactic Activity in Experimental Plasmodium berghei-Infected Mice. 树皮乙醇提取物对实验性疟原虫感染小鼠有显著的预防作用

IF 2

Drug Target Insights Pub Date : 2017-08-28 eCollection Date: 2017-01-01 DOI: 10.1177/1177392817728725

Olayinka O Otegbade, Johnson A Ojo, Dolapo I Adefokun, Oyindamola O Abiodun, Bolaji N Thomas, Olusola Ojurongbe

{"title":"Ethanol Extract of Blighia sapida Stem Bark Show Remarkable Prophylactic Activity in Experimental Plasmodium berghei-Infected Mice.","authors":"Olayinka O Otegbade, Johnson A Ojo, Dolapo I Adefokun, Oyindamola O Abiodun, Bolaji N Thomas, Olusola Ojurongbe","doi":"10.1177/1177392817728725","DOIUrl":"10.1177/1177392817728725","url":null,"abstract":"This work explores the antiplasmodial potential of ethanol extract of Blighia sapida (Lin. Sapindaceae) in chloroquine (CQ)-resistant Plasmodium berghei (ANKA strain)-infected mice. Chloroquine-resistant (ANKA) strain of P berghei was inoculated intraperitoneally into Swiss albino mice. Mice were treated orally for 4 consecutive days, before and after inoculation (prophylactic, suppressive, and curative models) with graded doses of the plant extracts with Artemether-Lumefantrine (Coartem) as control. Prophylactically, the extract showed a remarkable activity in the chemosuppression of P berghei parasites (P < .01) ranging from 57% to 36.5% at doses of 200 to 800 mg/kg, respectively, whereas Coartem (10 mg/kg) produced 62.1% chemosuppression. No significant chemosuppression was observed in the curative and suppressive models. The plant extract appeared to be safe at the highest dose tested (5000 mg/kg) for acute toxicity, with no adverse effect on the different organs. The plant extract possesses prophylactic antimalarial activity, which supports its use in the prevention of malaria.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"11 ","pages":"1177392817728725"},"PeriodicalIF":2.0,"publicationDate":"2017-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/b8/10.1177_1177392817728725.PMC5576538.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35327847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modification of S-Adenosyl-l-Homocysteine as Inhibitor of Nonstructural Protein 5 Methyltransferase Dengue Virus Through Molecular Docking and Molecular Dynamics Simulation. 登革病毒非结构蛋白5甲基转移酶抑制剂s -腺苷-l-同型半胱氨酸的分子对接和分子动力学模拟修饰

IF 2.7

Drug Target Insights Pub Date : 2017-04-20 eCollection Date: 2017-01-01 DOI: 10.1177/1177392817701726

Usman Sumo Friend Tambunan, Mochammad Arfin Fardiansyah Nasution, Fauziah Azhima, Arli Aditya Parikesit, Erwin Prasetya Toepak, Syarifuddin Idrus, Djati Kerami

{"title":"Modification of S-Adenosyl-l-Homocysteine as Inhibitor of Nonstructural Protein 5 Methyltransferase Dengue Virus Through Molecular Docking and Molecular Dynamics Simulation.","authors":"Usman Sumo Friend Tambunan, Mochammad Arfin Fardiansyah Nasution, Fauziah Azhima, Arli Aditya Parikesit, Erwin Prasetya Toepak, Syarifuddin Idrus, Djati Kerami","doi":"10.1177/1177392817701726","DOIUrl":"https://doi.org/10.1177/1177392817701726","url":null,"abstract":"Dengue fever is still a major threat worldwide, approximately threatening two-fifths of the world's population in tropical and subtropical countries. Nonstructural protein 5 (NS5) methyltransferase enzyme plays a vital role in the process of messenger RNA capping of dengue by transferring methyl groups from S-adenosyl-l-methionine to N7 atom of the guanine bases of RNA and the RNA ribose group of 2'OH, resulting in S-adenosyl-l-homocysteine (SAH). The modification of SAH compound was screened using molecular docking and molecular dynamics simulation, along with computational ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) test. The 2 simulations were performed using Molecular Operating Environment (MOE) 2008.10 software, whereas the ADME-Tox test was performed using various software. The modification of SAH compound was done using several functional groups that possess different polarities and properties, resulting in 3460 ligands to be docked. After conducting docking simulation, we earned 3 best ligands (SAH-M331, SAH-M2696, and SAH-M1356) based on ΔGbinding and molecular interactions, which show better results than the standard ligands. Moreover, the results of molecular dynamics simulation show that the best ligands are still able to maintain the active site residue interaction with the binding site until the end of the simulation. After a series of molecular docking and molecular dynamics simulation were performed, we concluded that SAH-M1356 ligand is the most potential SAH-based compound to inhibit NS5 methyltransferase enzyme for treating dengue fever.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"11 ","pages":"1177392817701726"},"PeriodicalIF":2.7,"publicationDate":"2017-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1177392817701726","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34966272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Gentamicin-Impregnated Collagen Sponge: Effectiveness in Preventing Sternal Wound Infection in High-Risk Cardiac Surgery. 庆大霉素浸渍胶原蛋白海绵预防高危心脏手术胸骨伤口感染的效果。

IF 2.7

Drug Target Insights Pub Date : 2016-05-29 eCollection Date: 2016-01-01 DOI: 10.4137/DTI.S39077

Filippo Rapetto, Vito D Bruno, Gustavo Guida, Roberto Marsico, Pierpaolo Chivasso, Carlo Zebele

引用次数: 15

A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab. 1例组织性肺炎(OP)与派姆单抗相关

IF 2.7

Drug Target Insights Pub Date : 2016-05-22 eCollection Date: 2016-01-01 DOI: 10.4137/DTI.S31565

Paraskevi Fragkou, Maria Souli, Maria Theochari, Christina Kontopoulou, Stelios Loukides, Anna Koumarianou

引用次数: 31

Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis 导论:药物洗脱支架还是药物洗脱移植物?来自蛋白质组学分析的见解

IF 2.7

Drug Target Insights Pub Date : 2016-01-03 DOI: 10.33393/dti.2016.1424

引用次数: 0

Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin–Angiotensin–Aldosterone System Blockers 利格列汀在使用肾素-血管紧张素-醛固酮系统阻滞剂的晚期糖尿病肾病患者中的疗效和安全性

IF 2.7

Drug Target Insights Pub Date : 2016-01-01 DOI: 10.4137/DTI.S38339

Yuichiro Ueda, Hiroki Ishii, Taisuke Kitano, Mitsutoshi Shindo, Haruhisa Miyazawa, K. Ito, Keiji Hirai, Y. Kaku, H. Mori, T. Hoshino, S. Ookawara, M. Kakei, K. Tabei, Yoshiyuki Morishita

{"title":"Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin–Angiotensin–Aldosterone System Blockers","authors":"Yuichiro Ueda, Hiroki Ishii, Taisuke Kitano, Mitsutoshi Shindo, Haruhisa Miyazawa, K. Ito, Keiji Hirai, Y. Kaku, H. Mori, T. Hoshino, S. Ookawara, M. Kakei, K. Tabei, Yoshiyuki Morishita","doi":"10.4137/DTI.S38339","DOIUrl":"https://doi.org/10.4137/DTI.S38339","url":null,"abstract":"Background We investigated the effects and safety of linagliptin as an add-on therapy in patients with advanced-stage diabetic nephropathy (DMN) taking renin–angiotensin–aldosterone system (RAAS) blockers. Method Twenty advanced-stage DMN patients (estimated glomerular filtration rate (eGFR): 24.5 ± 13.4 mL/min/1.73 m2) taking RAAS blockers were administered 5 mg/day linagliptin for 52 weeks. Changes in glucose and lipid metabolism and renal function were evaluated. Results Linagliptin decreased glycosylated hemoglobin levels (from 7.32 ± 0.77% to 6.85 ± 0.87%, P < 0.05) without changing fasting blood glucose levels, and significantly decreased total cholesterol levels (from 189.6 ± 49.0 to 170.2 ± 39.2 mg/dL, P < 0.05) and low-density lipoprotein cholesterol levels (from 107.1 ± 32.4 to 90.2 ± 31.0 mg/dL, P < 0.05) without changing high-density lipoprotein cholesterol and triglyceride levels. Urine protein/creatinine ratio and annual change in eGFR remained unchanged. No adverse effects were observed. Conclusion Linagliptin as an add-on therapy had beneficial effects on glucose and lipid metabolism without impairment of renal function, and did not have any adverse effects in this population of patients with advanced-stage DMN taking RAAS blockers.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"10 1","pages":"13 - 18"},"PeriodicalIF":2.7,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/DTI.S38339","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70698731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES: Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis 药物洗脱装置的最新进展:导论:药物洗脱支架还是药物洗脱移植物?来自蛋白质组学分析的见解

IF 2.7

Drug Target Insights Pub Date : 2016-01-01 DOI: 10.4137/DTI.S41240

C. Spadaccio, F. Nappi, N. Al-Attar, R. Coccia, M. Perluigi, F. Di Domenico

引用次数: 7